joae tirzepatide glp-1 Stopping Receptor Agonists… Why and How to Plan an “Exit Strategy” for Your Patients Menopause Hormone Therapy May Boost

Macroautophagy is defective in mucolipin-1-deficient mouse neurons

Other concerning features that warrant prompt medical attention include: new headache onset after age 50, headache during pregnancy or postpartum period, headache with fever or neck stiffness, headache following head trauma, headache in immunocompromised patients, and headache that worsens with position changes or Valsalva maneuver (coughing, straining)

Clinical Evidence on Combining GLP-1 Agonists With Growth Hormone Peptides Published clinical trials on sermorelin plus GLP-1 receptor agonists are limited, but emerging real-world evidence suggests combination therapy can be tolerated in carefully selected patients

Furthermore, in January 2025, the FDA approved semaglutide (Ozempic ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)